📣 VC round data is live. Check it out!
- Public Comps
- Fulgent Genetics
Fulgent Genetics Valuation Multiples
Discover Fulgent Genetics' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Genfit, Integral Diagnostics, Pacific Biosciences, Mirxes Holding and more.
Fulgent Genetics Overview
About Fulgent Genetics
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Founded
2016
HQ

Employees
1.3K
Website
Financials (LTM)
EV
$265M
Valuation Multiples
Start free trialFulgent Genetics Financials
Fulgent Genetics reported last 12-month revenue of $335M and negative EBITDA of ($29M).
In the same LTM period, Fulgent Genetics generated $133M in gross profit, ($29M) in EBITDA losses, and had net loss of ($73M).
Revenue (LTM)
Fulgent Genetics P&L
In the most recent fiscal year, Fulgent Genetics reported revenue of $323M and EBITDA of ($10M).
Fulgent Genetics is unprofitable as of last fiscal year, with gross margin of 41%, EBITDA margin of (3%), and net margin of (19%).
Financial data powered by Morningstar, Inc.
Fulgent Genetics Stock Performance
Fulgent Genetics has current market cap of $531M, and enterprise value of $265M.
Market Cap Evolution
Fulgent Genetics' stock price is $18.70.
Fulgent Genetics share price increased by 3.1% in the last 30 days, and decreased by 5.9% in the last year.
Fulgent Genetics has an EPS (earnings per share) of $-2.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $265M | $531M | 3.4% | 3.1% | 17.6% | -5.9% | $-2.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFulgent Genetics Valuation Multiples
Fulgent Genetics trades at 0.8x EV/Revenue multiple, and (9.1x) EV/EBITDA.
EV / Revenue (LTM)
Fulgent Genetics Financial Valuation Multiples
As of June 3, 2026, Fulgent Genetics has market cap of $531M and EV of $265M.
Fulgent Genetics has a P/E ratio of (7.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Fulgent Genetics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Fulgent Genetics Margins & Growth Rates
Fulgent Genetics grew revenue by 9% and EBITDA by 450% in the last fiscal year.
In the most recent fiscal year, Fulgent Genetics reported gross margin of 41%, EBITDA margin of (3%), and net margin of (19%).
Fulgent Genetics Margins
Fulgent Genetics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Fulgent Genetics Operational KPIs
Fulgent Genetics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Fulgent Genetics' Rule of 40 is (6%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fulgent Genetics' Rule of X is 7% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Fulgent Genetics Competitors
Fulgent Genetics competitors include Genfit, Integral Diagnostics, Pacific Biosciences, Mirxes Holding, Castle Biosciences, Indisa, Assure Tech, Abclon, Jiangsu Bioperfectus and Myriad Genetics.
Most Fulgent Genetics public comparables operate across Diagnostics & Genomics, Laboratory Services, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.8x | 6.2x | (16.0x) | (48.5x) | |||
| 2.2x | 1.7x | 12.5x | 8.4x | |||
| 5.7x | 5.6x | (6.0x) | (6.6x) | |||
| 19.4x | - | (5.6x) | - | |||
| 1.1x | 1.1x | 8.6x | 14.4x | |||
| 1.8x | - | 15.5x | - | |||
| 5.5x | - | 20.3x | - | |||
| 130.0x | - | (37.5x) | - | |||
This data is available for Pro users. Sign up to see all Fulgent Genetics competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Fulgent Genetics
Fulgent Genetics has acquired 6 companies to date.
Last acquisition by Fulgent Genetics was on December 22nd 2025. Fulgent Genetics acquired StrataDx for undisclosed valuation.
Latest Acquisitions by Fulgent Genetics
| Description | - | Bako Diagnostics provides specialized diagnostic and therapeutic services targeting skin, soft tissue, and bone pathologies of the lower extremity, with its expert pathology team supplying actionable insights to improve podiatric care outcomes. | Fulgent Pharma is a Los Angeles-headquartered clinical-stage biopharmaceutical company developing oncology therapeutics. Its pipeline includes FG-324, a next-generation antibody-drug conjugate targeting claudin-18.2 for gastric and pancreatic cancers, and torcetrapib derivatives for solid tumors. A subsidiary of Fulgent Genetics since 2021, it advances candidates through Phase 1 trials with support from precision diagnostics. | Inform Diagnostics is a Irving, Texas-headquartered anatomic pathology laboratory serving gastroenterologists, urologists, and dermatologists across the United States. The company processes over 1 million biopsies annually, offering molecular testing, digital pathology, and quality assurance programs through CAP-accredited facilities in multiple states. | |
| HQ Country | |||||
| HQ City | - | Alpharetta, GA | Los Angeles, CA | Dallas, TX | |
| Deal Date | 22 Dec 2025 | 22 Dec 2025 | 7 Nov 2022 | 18 Apr 2022 | |
| Valuation | undisclosed | $56M | $100M | $170M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Fulgent Genetics acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Fulgent Genetics
Fulgent Genetics has invested in 2 companies to date.
Latest investment by Fulgent Genetics was on February 23rd 2022. Fulgent Genetics invested in Spatial Genomics in their $56M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Fulgent Genetics
| Description | Spatial Genomics is a Boston-based biotechnology company advancing spatial transcriptomics tools for analyzing gene expression in tissue context. The platform combines microscopy with sequencing to map cellular interactions, serving research labs studying cancer and neuroscience worldwide. | Helio Health is an Irvine, California-headquartered diagnostics company commercializing AI-analyzed blood tests for early detection of liver, colon, breast, and lung cancers. It operates CLIA-certified labs in Irvine and West Lafayette, Indiana, providing physicians with actionable insights from liquid biopsies. |
| HQ Country | ||
| HQ City | Los Angeles, CA | Los Angeles, CA |
| Deal Date | 23 Feb 2022 | 15 Jul 2021 |
| Round | Series A | Series B |
| Raised | $56M | $118M |
| Investors | 12 West Capital; Fulgent Genetics | Fulgent Genetics; Samsung Securities |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Fulgent Genetics investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Fulgent Genetics
| When was Fulgent Genetics founded? | Fulgent Genetics was founded in 2016. |
| Where is Fulgent Genetics headquartered? | Fulgent Genetics is headquartered in United States. |
| How many employees does Fulgent Genetics have? | As of today, Fulgent Genetics has over 1K employees. |
| Who is the CEO of Fulgent Genetics? | Fulgent Genetics' CEO is Ming Hsieh. |
| Is Fulgent Genetics publicly listed? | Yes, Fulgent Genetics is a public company listed on Nasdaq. |
| What is the stock symbol of Fulgent Genetics? | Fulgent Genetics trades under FLGT ticker. |
| When did Fulgent Genetics go public? | Fulgent Genetics went public in 2016. |
| Who are competitors of Fulgent Genetics? | Fulgent Genetics main competitors include Genfit, Integral Diagnostics, Pacific Biosciences, Mirxes Holding, Castle Biosciences, Indisa, Assure Tech, Abclon, Jiangsu Bioperfectus, Myriad Genetics. |
| What is the current market cap of Fulgent Genetics? | Fulgent Genetics' current market cap is $531M. |
| What is the current revenue of Fulgent Genetics? | Fulgent Genetics' last 12 months revenue is $335M. |
| What is the current revenue growth of Fulgent Genetics? | Fulgent Genetics revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Fulgent Genetics? | Current revenue multiple of Fulgent Genetics is 0.8x. |
| Is Fulgent Genetics profitable? | No, Fulgent Genetics is not profitable. |
| What is the current EBITDA of Fulgent Genetics? | Fulgent Genetics has negative EBITDA and is not profitable. |
| What is Fulgent Genetics' EBITDA margin? | Fulgent Genetics' last 12 months EBITDA margin is (9%). |
| What is the current EV/EBITDA multiple of Fulgent Genetics? | Current EBITDA multiple of Fulgent Genetics is (9.1x). |
| How many companies Fulgent Genetics has acquired to date? | As of June 2026, Fulgent Genetics has acquired 6 companies. |
| What was the largest acquisition by Fulgent Genetics? | $170M acquisition of Inform Diagnostics on 18th April 2022 was the largest M&A Fulgent Genetics has done to date. |
| What companies Fulgent Genetics acquired? | Fulgent Genetics acquired Inform Diagnostics, Fulgent Pharma, Bako Diagnostics, CSI Laboratories, FF Gene Biotech, and StrataDx. |
| In how many companies Fulgent Genetics has invested to date? | As of June 2026, Fulgent Genetics has invested in 2 companies. |
| What was the last Fulgent Genetics investment? | On 23rd February 2022 Fulgent Genetics invested in Spatial Genomics, participating in a $56M Series A round, alongside 12 West Capital. |
| In what companies Fulgent Genetics invested in? | Fulgent Genetics invested in Helio Health and Spatial Genomics. |
See public comps similar to Fulgent Genetics
Lists including Fulgent Genetics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
